Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The relevance of animal models in multiple sclerosis research.
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Episode 38 with Dr. Joseph Berger on progressive multifocal leukoencephalopathy
Episode 27 with Dr. Brenda Banwell on the new journal Multiple Sclerosis and Related Disorders
Integrating Acupuncture Within a Wellness Intervention for Women With Multiple Sclerosis: A Feasibility Study.
T(H)17 cytokines in autoimmune neuro-inflammation.
Testosterone treatment in multiple sclerosis: a pilot study.
GlaxoSmithKline Protocol Summaries: Firategrast
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
The natural history of primary progressive MS in British Columbia, Canada.
National MS Society: Sylvia Lawry Physician Fellowships
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Clinically isolated syndrome - Rethinking the diagnosis.
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Episode 39 with Dr. Joseph Berger on diagnostic dilemmas in MS
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Nancy Davis Foundation Annual MS Expo and Health Forum
Keystone Symposium: Neuroepigenetics
Best practice in the use of natalizumab in multiple sclerosis.
Environmental, modifiable risk factors for multiple sclerosis
Spotlight on teriflunomide.
Multiple sclerosis in Hispanics: a study of clinical disease expression.
IL-17 and Th17 Cells.
Treatment Choices in Optic Neuritis: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, or Other?
Pages
« first
‹ previous
…
50
51
52
53
54
55
56
57
58
…
next ›
last »
